3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Unknown
1
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms, Unknown Primary
1
Gastrointestinal Neoplasms
1
Interventions
Fluorouracil
145
Gemcitabine
141
Oxaliplatin
135
Capecitabine
133
Leucovorin
107
Irinotecan
99
Bevacizumab
92
Cetuximab
69
Cisplatin
67
pembrolizumab
61
Radiotherapy
60
Nivolumab
41
130-nm albumin-bound paclitaxel
41
Sorafenib
39
Docetaxel
34
Albumin-Bound Paclitaxel
31
Radiosurgery
28
Paclitaxel
27
Surgical Procedures, Operative
25
regorafenib
24
Erlotinib Hydrochloride
23
Panitumumab
22
Cyclophosphamide
21
Celecoxib
20
Trastuzumab
19
Radiation
18
Neoadjuvant Therapy
18
IFL protocol
18
atezolizumab
17
Carboplatin
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Mebendazole
×
Gastrointestinal
×
Clear all
NCT03628079
2020-01-22
RepoMeb
Repos Pharma
Phase 1/2
Terminated
11 enrolled